This is a non-material operational milestone for a CDMO program. No immediate stock catalyst. Monitor for future contract awards or expansions under the DoW program, and for the next quarterly earnings report for financial updates on the broader Horizon restructuring.
Price Chart
Executive Summary
Evotec SE announced the initiation of a Phase 1 clinical trial for JST-018, a monoclonal antibody cocktail targeting orthopoxviruses (including smallpox), developed under a U.S. Department of War contract. This is a program milestone for its Just-Evotec Biologics CDMO subsidiary, demonstrating platform execution, but it does not represent a near-term revenue catalyst or change to the company's financial outlook. The two previously announced DoW contracts have a combined potential value of up to $123.9 million, but no new contract value or financial guidance was disclosed in this filing.
Key Facts
- Evotec initiated a Phase 1 trial for JST-018, an orthopoxvirus antibody cocktail, under the U.S. Department of War's Accelerated Antibodies Program.
- The program was advanced from sequence selection through cGMP manufacturing at the J.POD Redmond facility.
- This is the second program under the DoW Accelerated Antibodies Program; the two contracts have a combined potential value of up to $123.9 million.
- The filing is a routine operational update with no new financial data, guidance changes, or material corporate events.
Financial Impact
No new financial figures disclosed. The two DoW contracts have a combined potential value of up to $123.9 million, but this was previously announced.
Risk Factors
- Phase 1 clinical trials have a high failure rate; JST-018 may not advance to later stages.
- The $123.9 million combined contract value is the maximum potential; actual revenue recognition depends on milestone achievement and may be spread over several years.
- The company faces ongoing challenges from a prior cyberattack and material weaknesses in internal controls, as noted in the 20-F cross-filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-106064 |
| Document: tm2625085d1_6k.htm | 0001104659-26-106064 |
| Document: 0001104659-26-106064-index-headers.html | 0001104659-26-106064 |
| Document: 0001104659-26-106064-index.html | 0001104659-26-106064 |
| Document: 0001104659-26-106064.txt | 0001104659-26-106064 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 6-K | $1.42 $1.38 | ▲ +2.82% | ▲ +1.71% | $1.57 (−10.56%) |
Oct 14, 2026 13d ago | SC 13D/A | $1.42 $1.38 | ▲ +2.82% | ▲ +1.71% | $1.57 (−10.56%) |
Oct 14, 2026 13d ago | 6-K | $1.43 $1.42 | ▲ +0.35% | ▲ +0.64% | $1.57 (−10.18%) |
Sep 29, 2026 28d ago | 6-K | $1.64 $1.71 | ▲ +4.27% | ▲ +4.47% | $1.57 (−4.27%) |
Sep 9, 2026 6w ago | 6-K | $1.81 $1.77 | ▼ −2.21% | ▼ −1.61% | $1.57 (−13.26%) |
Aug 13, 2026 10w ago | 6-K | $2.02 $1.96 | ▲ +2.97% | ▲ +2.77% | $1.57 (+22.28%) |
Jul 13, 2026 15w ago | Press Release | $2.43 $2.14 | ▲ +11.93% | ▲ +12.29% | $1.57 (+35.39%) |
Jun 30, 2026 17w ago | 6-K | $2.80 $2.85 | ▲ +1.79% | ▲ +1.92% | $1.57 (−43.93%) |
Jun 17, 2026 18w ago | 6-K | $2.61 $2.56 | ▼ −1.92% | ▼ −2.70% | $1.57 (−39.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers